Neidio i'r prif gynnwy

Canser a Gwaed

 Hepatobiliary Surgery, Service Specification (CP73), June 2021.pdf (PDF, 318Kb)
 INTERIM Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®), Service Specification (CP175), March 2019.pdf (PDF, 514Kb)
 INTERIM Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification, (CP176), March 2019.pdf (PDF, 571Kb)
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), September 2020.pdf (PDF, 334Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Commissioning Policy (CP87b), August 2015.pdf (PDF, 918Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Service Specification (CP87a), August 2015.pdf (PDF, 817Kb)
 Molecular Radiotherapy Services (MRT) All Ages, Service Specification (SS291), March 2025.pdf (PDF, 710Kb)
 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification (CP266), March 2023.pdf (PDF, 300Kb)
 Positron Emission Tomography – Computed Tomography (PET-CT) (Fixed and Mobile Site), Service Specification (SS50), March 2025.pdf (PDF, 2.7Mb)
 Positron Emission Tomography (PET), Commissioning Policy (CP50), September 2025.pdf (PDF, 539Kb)
 Proton Beam Therapy for adults with cancer, Commissioning Policy (CP147), July 2023.pdf (PDF, 279Kb)
 Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023.pdf (PDF, 231Kb)
 Radiofrequency Ablation (RFA) for the management of Barrett's Oesophagus in Adults, Commissioning Policy (CP183), June 2025.pdf (PDF, 532Kb)
 Radiofrequency Ablation (RFA) for the management of Barrett's Oesophagus in Adults, Service Specification (SS183), June 2025.pdf (PDF, 513Kb)
 Rituximab and Eculizumab for the prevention and management of delayed haemolytic tranfusion reactions and hyperhaemolysis in people with hereditary anaemias, Policy Position Statement (PP237), February 2023 (PDF, 454Kb)
 Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173), June 2020.pdf (PDF, 188Kb)
 Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma (PPS227), Policy Position Statement, November 2021.pdf (PDF, 276Kb)
 Services for Children with Cancer, Service Specification (SS86), December 2024.pdf (PDF, 509Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other rare hereditary anaemias all ages, Service Specification (CP179), December 2020.pdf (PDF, 453Kb)
 Soft tissue sarcoma, Service Specification (SS149), November 2025 (PDF, 556Kb)